Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...

The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon ...

Adding atezolizumab to chemo in stage 3 dMMR colon cancer halves the risk of recurrence, marking a major step in precision ...

To assess T-cell-induced morphological changes, each organoid was segmented in the transmitted light (TL) channel using a ...

Adding atezolizumab to standard adjuvant chemotherapy significantly delayed recurrence or death for individuals with stage ...

Recent trials unveil significant advances in cancer treatment with immunotherapy drug Tecentriq, showing a 50% reduction in ...

The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

New phase 1 findings highlight promise of first-in-class bispecific antibody fusion for advanced colorectal cancer.